For the early detection of myocardial damage associated with anthracycline therapy, electrocardiography, echocardiography, and radionuclide angiocardiography were used to assess cardiac function in 37 patients receiving anthracyclines (ie, adriamycin and daunorubicin at a total dose of 100-2,030 mg/m2). None of the patients developed clinical congestive heart failure. There were no significant changes of electrocardio graphic and echocardiographic parameters after anthracycline administration. The left ventricular ejection fraction did not change significantly on radionuclide angiocardiog raphy. However, the 1/3 peak filling rate (PFR) corrected by the end-diastolic count (EDC) (1/3 PFR/EDC) and the 1/3 filling fraction (1/3 FF), the indices of early diastolic function, showed a significant decrease. These findings suggest that the 1/3 PFR/EDC and 1/3 FF determined by radionuclide imaging are useful for detecting silent myocardial damage induced by anthracyclines.
Get full access to this article
View all access options for this article.
References
1.
Tan C., Etcubanas E., Wollner N., et al: Adriamycin— an antitumor antibiotic in treatment of neoplastic diseases. Cancer32:9-17, 1973.
2.
Young RC, Ozols RF, Myers CE, et al: The anthracycline antineoplastic drugs. N Engl J Med305:139-153, 1981.
3.
Lefrak EA, Pitha J., Rosenheim S., et al: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer32:302-314, 1973.
4.
Halazum JF, Wagner HR, Gaeta JF, et al: Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia. Cancer33:545-554, 1974.
5.
Lenaz T.: Doxorubicin cardiotoxicity. Cancer Treat Rev3:111-120, 1976.
6.
Von Hoff DD, Rozencweig M., Layard M., et al: Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med62:200-208, 1977.
7.
Bristow MR, Billingham ME, Mason JW, et al: Clinical spectrum of anthracycline antibiotic cardiotoxicity . Cancer Treat Rep62:873-879, 1978.
8.
Von Hoff DD, Layard MW, Basa P., et al: Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med91:710-717, 1979.
9.
Praga C., Beretta G., Vigo PL, et al: Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep63:827-834, 1979.
10.
Goorin AM, Borow KM, Goldman A., et al: Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children. Cancer47:2810-2816, 1981.
11.
Watts RG: Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: Evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol36:217-218, 1991.
12.
Minow RA, Benjamin RS, Gottlieb JA: Adriamycin (NSC-123127) cardiomyopathy—an overview with determination of risk factors. Cancer Chemother Rep6:195-201, 1975.
13.
Bender KS, Shematek JP, Leventhal BG, et al: QT interval prolongation associated with anthracycline cardiotoxicity . J Pediatr105:442-444, 1984.
14.
Schwartz CL, Hobbie WL, Truesdell S., et al: Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol11:1906-1910, 1993.
15.
Lewis AB, Pilkington R., Takahashi M., et al: Echocardiographic assessment of anthracycline cardiotoxicity in children. Med Pediatr Oncol5:167-175, 1978.
16.
Bloom KR, Bini RM, Williams CM, et al: Echocardiography in adriamycin cardiotoxicity. Cancer41:1265-1269, 1978.
17.
Weesner KM, Bledsoe M., Chauvenet A., et al: Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer68:435-438, 1991.
18.
Marchandise B., Schroeder E., Bosly A., et al: Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J118:92-98, 1989.
19.
Bu'Lock FA, Mott MG, Oakhill A., et al: Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relation with systolic function, symptoms, and pathophysiology . Br Heart J73:340, 1995.
20.
Ritchie JL, Singer JW, Thorning D., et al: Anthracycline cardiotoxicity: Clinical and pathological outcomes assessed by radionuclide ejection fraction. Cancer46:1109-1116, 1980.
21.
Schwartz RG , McKenzie WB, Alexander J., et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med82:1109, 1987.
22.
Piver MS, Marchetti DL, Parthasarathy KL, et al: Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer56:76-80, 1985.
23.
Parmentier S., Melin JA, Piret L., et al: Assessment of left ventricular diastolic function in patients receiving anthracycline therapy. Eur J Nucl Med13:563-567, 1988.
24.
Ganz WI, Sridhar KS, Forness TJ: Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol16:109-112, 1993.
25.
Bristow MR, Mason JW, Billingham ME, et al: Doxorubicin cardiomyopathy: Evaluation by phono-cardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med88:168-175, 1978.
26.
Ewer MS, Ali MK, Mackay B., et al: A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol2:112-117, 1984.
27.
Allen A.: The cardiotoxicity of chemotherapeutic drugs. Semin Oncol19:529-542, 1992.
28.
Steinberg JS , Wasserman AG: Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity. Clin Ther7:660-667, 1985.
29.
Basser RL, Green MD: Complications of treatment. Strategies for prevention of anthracycline cardiotoxicity . Cancer Treat Rev19:57-77, 1993.
30.
Devereux RB , Reichek N.: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation55:613-618, 1977.
31.
Heger JJ, Weyman AE, Wann LS, et al: Cross-sectional echocardiography in acute myocardial infarction: Detection and localization of regional left ventricular asynergy. Circulation60:531-538, 1979.
32.
Spirito P., Maron BJ, Bonow RO: Noninvasive assessment of left ventricular diastolic function: Comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques . J Am Coll Cardiol7:518-526, 1986.
33.
Granier P., Esquerre JP, Tredez P., et al: Correlations between M-mode markers of left ventricular hypertrophy and radionuclide angiographic indices of left ventricular diastolic function in mild to moderate hypertension. J Hypertens7 (suppl 6):s100-s101, 1989.
34.
Harrison RM , Clifton DG, Pennell TA, et al: Effect of heart rate on left ventricular diastolic transmitral flow velocity patterns assessed by Doppler echocardiography . Am J Cardiol67:622, 1991.
35.
Triulzi OM, Castini D., Ornaghi M., et al: Effects of preload reduction on mitral flow velocity pattern in normal subjects. Am J Cardiol66:995-1001, 1990.
36.
Miyaguchi K. , Iwase M., Yokota M., et al: Dependency of the pulsed Doppler-derived transmitral fillings profile on the sampling site. Am Heart J122:142-148, 1991.
37.
Jaffe MW, Dewhurst AT, Otto MC, et al: Influence of Doppler sample volume location on ventricular filling velocities. Am J Cardiol68:550-552, 1991.
38.
Sakata K., Kashiro S., Hirata S., et al: Prognostic value of Doppler transmitral flow velocity patterns in acute myocardial infarction. Am J Cardiol79:1165-1169, 1997.
39.
Fukazawa R. , Ogawa S., Hirayama T.: Early detection of anthracycline cardiotoxicity in children with acute leukemia using exercise-based echocardiography and Doppler echocardiography. Jpn Circ J58:625-634, 1994.
40.
Harizi RC, Bianco JA, Alpert JS: Diastolic function of the heart in clinical cardiology. Arch Intern Med148:99-109, 1988.
41.
Villari B., Betocchi S., Pace L., et al: Assessment of left ventricular diastolic function. Comparison of contrast ventriculography and equilibrium radionuclide angiography. J Nucl Med32:1849-1853, 1991.
42.
Polak JF, Kemper AJ, Bianco JA, et al: Resting early peak diastolic filling rate: A sensitive index of myocardial dysfunction in patients with coronary artery disease. J Nucl Med23:471-478, 1982.
